PT1265860E - Compostos amidino uteis como inibidores de sintase de oxido nitrico - Google Patents
Compostos amidino uteis como inibidores de sintase de oxido nitricoInfo
- Publication number
- PT1265860E PT1265860E PT01922636T PT01922636T PT1265860E PT 1265860 E PT1265860 E PT 1265860E PT 01922636 T PT01922636 T PT 01922636T PT 01922636 T PT01922636 T PT 01922636T PT 1265860 E PT1265860 E PT 1265860E
- Authority
- PT
- Portugal
- Prior art keywords
- uteis
- nitric oxide
- oxide synthase
- synthase inhibitors
- amidine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19192300P | 2000-03-24 | 2000-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1265860E true PT1265860E (pt) | 2005-10-31 |
Family
ID=22707469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01922636T PT1265860E (pt) | 2000-03-24 | 2001-03-23 | Compostos amidino uteis como inibidores de sintase de oxido nitrico |
Country Status (22)
Country | Link |
---|---|
US (5) | US6403830B2 (pt) |
EP (2) | EP1265860B1 (pt) |
JP (2) | JP4205340B2 (pt) |
KR (1) | KR100835265B1 (pt) |
CN (1) | CN1294117C (pt) |
AR (1) | AR033359A1 (pt) |
AT (2) | ATE295832T1 (pt) |
AU (4) | AU4774501A (pt) |
BR (1) | BR0109386A (pt) |
CA (2) | CA2402199C (pt) |
DE (2) | DE60116067T2 (pt) |
DK (2) | DK1265859T3 (pt) |
ES (2) | ES2256223T3 (pt) |
GE (1) | GEP20094625B (pt) |
HK (2) | HK1050521A1 (pt) |
MX (1) | MXPA02009282A (pt) |
MY (1) | MY135721A (pt) |
NZ (4) | NZ520813A (pt) |
PT (1) | PT1265860E (pt) |
TW (1) | TWI294417B (pt) |
WO (2) | WO2001072703A1 (pt) |
ZA (2) | ZA200206459B (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200206459B (en) * | 2000-03-24 | 2003-08-13 | Pharmacia Corp | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors. |
US7393652B2 (en) | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
US7012098B2 (en) * | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
AU2002307217A1 (en) * | 2001-03-28 | 2002-10-15 | University Of South Florida | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
US7695736B2 (en) * | 2001-04-03 | 2010-04-13 | Pfizer Inc. | Reconstitutable parenteral composition |
DE10141650C1 (de) * | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20030109522A1 (en) * | 2001-09-24 | 2003-06-12 | Manning Pamela T. | Ophthalmologic treatment methods using selective iNOS inhibitors |
US20030119826A1 (en) * | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
KR20050044459A (ko) * | 2001-11-13 | 2005-05-12 | 파마시아 코포레이션 | 파레콕시브 등의 설폰아미드 선구약물의 경구 투여 형태 |
MXPA04011335A (es) * | 2002-05-16 | 2005-07-01 | Pharmacia Corp | Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto. |
JP2005536467A (ja) * | 2002-05-16 | 2005-12-02 | ファルマシア・コーポレーション | 選択的iNOS阻害剤を用いる呼吸器の疾患および状態の治療方法 |
CA2486350A1 (en) | 2002-06-05 | 2003-12-24 | Kaneka Corporation | Process for producing optically active .alpha.-methylcysteine derivative |
BR0313204A (pt) * | 2002-08-02 | 2005-06-28 | Pharmacia Corp | Métodos para tratamento e prevenção de condições gastrointestinais |
AU2003269406A1 (en) * | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Process for preparing s-(2-aminoethyl)-2-methyl-l-cysteine |
US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
WO2004060352A1 (en) * | 2002-12-19 | 2004-07-22 | Pharmacia Corporation | Non-hygroscopic formulation comprising a hydroscopic drug |
WO2004064767A2 (en) * | 2003-01-23 | 2004-08-05 | Kahn Nighat N | Nitric oxide inducing agents |
DE10308580B3 (de) * | 2003-02-27 | 2004-09-09 | Consortium für elektrochemische Industrie GmbH | Verfahren zur elektrophilen Substitution von Thiazolidinen oder Oxazolidinen |
JP2007525165A (ja) | 2003-03-07 | 2007-09-06 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | タイプ1ライアノジン受容体に基づく方法 |
BRPI0408182A (pt) * | 2003-03-11 | 2006-03-21 | Pharmacia Corp | sal cristalino monoidrato de salicilato de s-[2-[(1-iminoetil)amino]etil]-2-metil-l-cisteìna |
MXPA05009244A (es) * | 2003-03-11 | 2005-10-19 | Pharmacia Corp | Procedimientos para la eliminacion selectiva de contraiones de compuestos y compuestos derivados de esos procedimientos. |
CN100460387C (zh) * | 2003-03-11 | 2009-02-11 | 法马西亚公司 | 盐酸s-[2-[(1-亚氨基乙基)氨基]乙基]-2-甲基-l-半胱氨酸马来酸盐结晶盐 |
WO2004080955A1 (en) * | 2003-03-11 | 2004-09-23 | Pharmacia Corporation | S-[2-[1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate crystalline salt |
JP2006519839A (ja) * | 2003-03-11 | 2006-08-31 | ファルマシア・コーポレーション | S−[2−[(1−イミノエチル)アミノ]エチル]−2−メチル−l−システインマレエートii型結晶塩 |
US20040186046A1 (en) * | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
JP4577513B2 (ja) * | 2003-04-08 | 2010-11-10 | 三菱瓦斯化学株式会社 | 2−アルキルシステインアミド又はその塩、並びに、それらの製造方法及び用途 |
DE602004023534D1 (de) * | 2003-11-18 | 2009-11-19 | Mitsubishi Gas Chemical Co | Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
US20060154981A1 (en) * | 2005-01-12 | 2006-07-13 | Alcon, Inc. | Method of reducing intraocular pressure and treating glaucoma |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
EP1986656A4 (en) * | 2006-02-02 | 2012-05-16 | Univ South Florida | WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER |
EP2001881A2 (en) * | 2006-03-07 | 2008-12-17 | Endacea, Inc. | Compositions and methods for treating respiratory disorders |
WO2007108004A2 (en) * | 2006-03-23 | 2007-09-27 | Meditor Pharmaceuticals Ltd. | S-alkylisothiouronium derivatives for the treatment of inflammatory diseases |
US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
CN101758337B (zh) | 2009-12-03 | 2012-02-15 | 湖南阿斯达生化科技有限公司 | 一种助焊剂用非卤素活性剂 |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
JP6034283B2 (ja) | 2010-03-26 | 2016-11-30 | トラスティーズ・オブ・ダートマス・カレッジ | Vista制御性t細胞メディエータタンパク質、vista結合剤、およびその使用 |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US9293197B2 (en) | 2011-08-15 | 2016-03-22 | Lockheed Martin Corporation | Reconfigurable phase change material masks for electro-optical compressive sensing |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014039983A1 (en) | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
US9340446B1 (en) | 2013-02-04 | 2016-05-17 | Lockheed Martin Corporation | Optical apparatus and method of forming a gradient index device |
SG11201509022XA (en) | 2013-05-02 | 2015-12-30 | Api Corp | METHOD FOR PRODUCING α-SUBSTITUTED CYSTEINE OR SALT THEREOF OR INTERMEDIATE FOR SYNTHESIS OF α-SUBSTITUTED CYSTEINE |
US10500176B2 (en) * | 2013-09-13 | 2019-12-10 | Replicon Health Oy | Method for enhancing energy production and metabolism in cells |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2015097536A2 (en) | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
US10437083B1 (en) | 2014-10-20 | 2019-10-08 | Lockheed Martin Corporation | Individually addressable infrared mask array |
CN107405398A (zh) | 2014-12-05 | 2017-11-28 | 伊穆奈克斯特股份有限公司 | 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途 |
EP3313882B1 (en) | 2015-06-24 | 2020-03-11 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
MX2018009800A (es) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos. |
JP7184751B2 (ja) | 2016-04-15 | 2022-12-06 | イミュネクスト インコーポレイテッド | 抗ヒトvista抗体およびその使用 |
US9969647B2 (en) | 2016-05-17 | 2018-05-15 | Lockheed Martin Energy, Llc | Glass composites having a gradient index of refraction and methods for production thereof |
US9908808B1 (en) | 2016-08-18 | 2018-03-06 | Lockheed Martin Corporation | Ternary glass materials with low refractive index variability |
EP3398941A1 (en) * | 2017-05-03 | 2018-11-07 | AXXAM S.p.A. | Heterocyclic p2x7 antagonists |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU636713B2 (en) | 1990-02-26 | 1993-05-06 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of nitric oxide biosynthesis |
US5132453A (en) | 1991-03-22 | 1992-07-21 | Cornell Research Foundation, Inc. | N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
DE4234867A1 (de) * | 1992-10-16 | 1994-04-21 | Degussa | Verfahren zur Herstellung von Aminoalkylhydantoin und Aminoalkyl-alpha-aminosäuren |
EP0670720A1 (en) | 1992-11-27 | 1995-09-13 | The Wellcome Foundation Limited | Enzyme inhibitors |
WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
DE4324088A1 (de) * | 1993-07-17 | 1995-01-19 | Hoechst Ag | Hochtemperatursupraleitende Massivkörper und Verfahren zu ihrer Herstellung |
AU688811B2 (en) | 1993-10-21 | 1998-03-19 | G.D. Searle & Co. | Amidino derivatives useful as nitric oxide synthase inhibitors |
DK0724435T3 (da) | 1993-10-21 | 2002-11-25 | Searle & Co | Amidinoderivater, der er nyttige som nitrogenoxid-synthase-inhibitorer |
GB9405211D0 (en) | 1994-03-17 | 1994-04-27 | Deas Alexander R | Noise cancellation apparatus |
DK0751930T3 (da) | 1994-03-24 | 2000-04-17 | Searle & Co | Amidinoderivater anvendelige som nitrogenoxid-synthase-inhibitorer |
AU692892B2 (en) * | 1994-06-15 | 1998-06-18 | Wellcome Foundation Limited, The | Enzyme inhibitors |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
US5684008A (en) | 1994-11-09 | 1997-11-04 | G. D. Searle & Co. | Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
CA2216882A1 (en) | 1995-04-20 | 1996-10-24 | G.D. Searle & Co. | Cyclic amidino agents useful as nitric oxide synthase inhibitors |
CN1190390A (zh) | 1995-05-10 | 1998-08-12 | G.D.瑟尔公司 | 由环状脒衍生的氧化氮合成酶抑制剂 |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
US5830917A (en) | 1995-09-11 | 1998-11-03 | G. D. Searle & Co. | L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors |
US5945408A (en) | 1996-03-06 | 1999-08-31 | G.D. Searle & Co. | Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors |
US5981511A (en) * | 1996-03-06 | 1999-11-09 | G.D. Searle & Co. | Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors |
MY117948A (en) * | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
SK13012000A3 (sk) | 1998-03-11 | 2001-06-11 | G. D. Searle & Co. | Halogenované deriváty amidinoaminokyselín použiteľné ako inhibítory no-syntázy |
GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
ZA200206459B (en) * | 2000-03-24 | 2003-08-13 | Pharmacia Corp | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors. |
-
2001
- 2001-03-23 ZA ZA200206459A patent/ZA200206459B/en unknown
- 2001-03-23 AU AU4774501A patent/AU4774501A/xx active Pending
- 2001-03-23 CN CNB018070655A patent/CN1294117C/zh not_active Expired - Fee Related
- 2001-03-23 WO PCT/US2001/009433 patent/WO2001072703A1/en active IP Right Grant
- 2001-03-23 DE DE60116067T patent/DE60116067T2/de not_active Expired - Lifetime
- 2001-03-23 US US09/816,577 patent/US6403830B2/en not_active Expired - Lifetime
- 2001-03-23 AU AU4941501A patent/AU4941501A/xx active Pending
- 2001-03-23 US US09/816,575 patent/US6586474B2/en not_active Expired - Lifetime
- 2001-03-23 EP EP01922636A patent/EP1265860B1/en not_active Expired - Lifetime
- 2001-03-23 NZ NZ520813A patent/NZ520813A/en not_active IP Right Cessation
- 2001-03-23 CA CA2402199A patent/CA2402199C/en not_active Expired - Fee Related
- 2001-03-23 AU AU2001249415A patent/AU2001249415B2/en not_active Ceased
- 2001-03-23 MX MXPA02009282A patent/MXPA02009282A/es active IP Right Grant
- 2001-03-23 EP EP01920718A patent/EP1265859B1/en not_active Expired - Lifetime
- 2001-03-23 DK DK01920718T patent/DK1265859T3/da active
- 2001-03-23 KR KR1020027012229A patent/KR100835265B1/ko not_active IP Right Cessation
- 2001-03-23 NZ NZ520812A patent/NZ520812A/en not_active IP Right Cessation
- 2001-03-23 GE GEAP200110668A patent/GEP20094625B/en unknown
- 2001-03-23 JP JP2001570616A patent/JP4205340B2/ja not_active Expired - Fee Related
- 2001-03-23 AR ARP010101388A patent/AR033359A1/es not_active Application Discontinuation
- 2001-03-23 AT AT01922636T patent/ATE295832T1/de active
- 2001-03-23 JP JP2001570615A patent/JP4216502B2/ja not_active Expired - Fee Related
- 2001-03-23 MY MYPI20011391A patent/MY135721A/en unknown
- 2001-03-23 AT AT01920718T patent/ATE313525T1/de active
- 2001-03-23 CA CA2402436A patent/CA2402436C/en not_active Expired - Fee Related
- 2001-03-23 NZ NZ532073A patent/NZ532073A/en not_active IP Right Cessation
- 2001-03-23 ES ES01920718T patent/ES2256223T3/es not_active Expired - Lifetime
- 2001-03-23 PT PT01922636T patent/PT1265860E/pt unknown
- 2001-03-23 DE DE60110902T patent/DE60110902T2/de not_active Expired - Lifetime
- 2001-03-23 DK DK01922636T patent/DK1265860T3/da active
- 2001-03-23 BR BR0109386-0A patent/BR0109386A/pt active Search and Examination
- 2001-03-23 AU AU2001247745A patent/AU2001247745B2/en not_active Ceased
- 2001-03-23 WO PCT/US2001/009431 patent/WO2001072702A2/en active IP Right Grant
- 2001-03-23 ES ES01922636T patent/ES2240445T3/es not_active Expired - Lifetime
- 2001-03-23 NZ NZ542734A patent/NZ542734A/en not_active IP Right Cessation
- 2001-05-29 TW TW090106982A patent/TWI294417B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 ZA ZA200206455A patent/ZA200206455B/en unknown
- 2002-12-17 US US10/321,969 patent/US7102013B2/en not_active Expired - Fee Related
-
2003
- 2003-04-16 HK HK03102774A patent/HK1050521A1/xx not_active IP Right Cessation
- 2003-11-17 HK HK03108370A patent/HK1056161A1/xx not_active IP Right Cessation
-
2004
- 2004-04-01 US US10/815,375 patent/US6914158B2/en not_active Expired - Lifetime
-
2005
- 2005-01-10 US US11/032,650 patent/US7196118B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1265860E (pt) | Compostos amidino uteis como inibidores de sintase de oxido nitrico | |
NO20032835L (no) | Nitrogenoksyd-syntase-inhibitor-fosfatsalt | |
NO20006044L (no) | Nitrogenoksid-syntaseinhibitorer | |
AR028575A1 (es) | Derivados de pirrolopiridinona utiles como inhibidores de fosfodiesterasa | |
DK1745052T3 (da) | HIV-intergrase-inhibitorer: cykliske pyrimidinonforbindelser | |
DE60211317D1 (de) | Rho-kinase inhibitoren | |
DE60218138D1 (de) | Rho-kinase inhibitoren | |
DE60320933D1 (de) | Rho-kinase inhibitoren | |
DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
AR028605A1 (es) | Compuesto quimico | |
ATE484496T1 (de) | Metalloproteinaseinhibitoren | |
EE04013B1 (et) | Lämmastikoksiidi süntaasi inhibiitorid | |
PT1401828E (pt) | Compostos de n-formil-hidroxilamina como inibidores de pdf | |
EE200300452A (et) | Metalloproteinaasi inhibiitorid | |
EE200000519A (et) | Lämmastikoksiidi süntaasi inhibiitoritena toimivad halogeenitud amidinoaminohappederivaadid | |
DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
BR0305192B1 (pt) | conversor de amônia | |
PT1395553E (pt) | Derivados de pirrolidina como inibidores do factor xa | |
NO20032807D0 (no) | Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer | |
PT1217002E (pt) | 2-(4-piridinil)-benzofuranos como inibidores de metaloproteases | |
EE9900474A (et) | Amidiini derivaadid lämmastikoksiidi süntaasi inhibiitoritena | |
PT1390351E (pt) | Derivados de pirimidina uteis como inibidores selectivos de cox-2 | |
NO20031091D0 (no) | Fremgangsmåte for lagring av ammoniakk | |
DE60009260D1 (de) | Thiopyranderivate as mmp-inhibitoren | |
DE10390373D2 (de) | Phosphorchelatverbindungen |